An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

Vignesh T. Packiam(University of Chicago), Donald L. Lamm(NRG Oncology), Daniel A. Barocas(Vanderbilt University), Andrew Trainer(Adult and Pediatric Dermatology), Benjamin Fand, Ronald L. Davis(Wake Forest University), William R. Clark(Alaska Neurology Center), Michael Kroeger(University of Nebraska Medical Center), Igor Dumbadze, Karim Chamie(University of California, Los Angeles), A. Karim Kader(University of California San Diego), Dominic Curran(Genesys (United States)), John Gutheil, Arthur Kuan(Genesys (United States)), Alex Yeung(Genesys (United States)), Gary D. Steinberg(University of Chicago)
Urologic Oncology Seminars and Original Investigations
July 26, 2017
Cited by 240

Abstract


Related Papers

No related papers found

Powered by citation graph analysis